What is Myelofibrosis?
Jan 22, 2014 EST
Novartis announced that patients with myelofibrosis initially randomized to treatment with Jakavi® (ruxolitinib) lived longer than those randomized to treatment with placebo or conventional therapy, as described in several analyses from the Phase III COMFORT-I and COMFORT-II studies. Results are being presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, LA.
